| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medulloblastoma | 42 | 2022 | 679 | 3.950 |
Why?
|
| Cerebellar Neoplasms | 33 | 2022 | 587 | 3.270 |
Why?
|
| Cranial Irradiation | 29 | 2022 | 390 | 2.400 |
Why?
|
| Brain Neoplasms | 63 | 2024 | 8981 | 1.590 |
Why?
|
| Ependymoma | 14 | 2023 | 320 | 1.530 |
Why?
|
| Radiotherapy, Conformal | 11 | 2014 | 549 | 1.120 |
Why?
|
| Hodgkin Disease | 36 | 2012 | 1377 | 1.060 |
Why?
|
| Craniopharyngioma | 11 | 2021 | 277 | 1.000 |
Why?
|
| Photons | 9 | 2015 | 581 | 0.990 |
Why?
|
| Pituitary Neoplasms | 12 | 2021 | 1313 | 0.960 |
Why?
|
| Radiotherapy Dosage | 51 | 2024 | 2896 | 0.920 |
Why?
|
| Neoplasms, Second Primary | 18 | 2014 | 1056 | 0.850 |
Why?
|
| Astrocytoma | 13 | 2005 | 775 | 0.850 |
Why?
|
| Radiation Injuries | 18 | 2021 | 1182 | 0.830 |
Why?
|
| Spinal Cord Neoplasms | 6 | 2023 | 263 | 0.760 |
Why?
|
| Child, Preschool | 147 | 2024 | 42058 | 0.750 |
Why?
|
| Rhabdomyosarcoma | 10 | 2014 | 358 | 0.710 |
Why?
|
| Neoplasms, Radiation-Induced | 14 | 2013 | 546 | 0.690 |
Why?
|
| Child | 180 | 2024 | 79813 | 0.690 |
Why?
|
| Germinoma | 8 | 2021 | 132 | 0.680 |
Why?
|
| Radiotherapy | 21 | 2015 | 1504 | 0.640 |
Why?
|
| Protons | 14 | 2024 | 1112 | 0.630 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 24 | 2004 | 1547 | 0.610 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 57 | 2021 | 11709 | 0.600 |
Why?
|
| Radiosurgery | 17 | 2005 | 1342 | 0.600 |
Why?
|
| Career Mobility | 3 | 2017 | 258 | 0.590 |
Why?
|
| Neuroectodermal Tumors, Primitive | 8 | 2015 | 136 | 0.560 |
Why?
|
| Central Nervous System Neoplasms | 7 | 2015 | 916 | 0.550 |
Why?
|
| Adolescent | 161 | 2024 | 87888 | 0.540 |
Why?
|
| Radiotherapy, Intensity-Modulated | 7 | 2022 | 801 | 0.540 |
Why?
|
| Cranial Nerve Neoplasms | 5 | 2006 | 134 | 0.520 |
Why?
|
| Combined Modality Therapy | 65 | 2022 | 8530 | 0.490 |
Why?
|
| Optic Nerve Glioma | 2 | 2006 | 32 | 0.480 |
Why?
|
| Retinoblastoma | 8 | 2014 | 317 | 0.470 |
Why?
|
| Faculty, Medical | 6 | 2021 | 1192 | 0.460 |
Why?
|
| Infratentorial Neoplasms | 6 | 2017 | 98 | 0.420 |
Why?
|
| Disease-Free Survival | 29 | 2022 | 6821 | 0.410 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 6 | 2021 | 494 | 0.400 |
Why?
|
| Glioma | 11 | 2019 | 3418 | 0.400 |
Why?
|
| Bone Marrow Transplantation | 18 | 2007 | 2693 | 0.400 |
Why?
|
| Radiotherapy, High-Energy | 6 | 2004 | 228 | 0.390 |
Why?
|
| Vincristine | 26 | 2015 | 1038 | 0.380 |
Why?
|
| Supratentorial Neoplasms | 5 | 2015 | 159 | 0.370 |
Why?
|
| Neoplasm Recurrence, Local | 26 | 2023 | 9273 | 0.370 |
Why?
|
| Infant | 74 | 2021 | 36054 | 0.370 |
Why?
|
| Methotrexate | 18 | 2012 | 1719 | 0.370 |
Why?
|
| Radiodermatitis | 2 | 2011 | 58 | 0.350 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 15 | 2022 | 1659 | 0.330 |
Why?
|
| Whole-Body Irradiation | 11 | 1998 | 433 | 0.320 |
Why?
|
| Bone Neoplasms | 12 | 2014 | 2531 | 0.320 |
Why?
|
| Physicians, Women | 5 | 2008 | 495 | 0.320 |
Why?
|
| Male | 191 | 2024 | 358742 | 0.320 |
Why?
|
| Optic Chiasm | 5 | 2014 | 91 | 0.310 |
Why?
|
| Neoplasm Staging | 25 | 2016 | 11152 | 0.300 |
Why?
|
| Female | 186 | 2024 | 390316 | 0.300 |
Why?
|
| Humans | 258 | 2024 | 758381 | 0.300 |
Why?
|
| Central Nervous System Cysts | 1 | 2007 | 56 | 0.290 |
Why?
|
| Etoposide | 7 | 2015 | 630 | 0.280 |
Why?
|
| Lens, Crystalline | 2 | 2007 | 388 | 0.280 |
Why?
|
| Follow-Up Studies | 52 | 2021 | 39060 | 0.270 |
Why?
|
| Orbital Neoplasms | 3 | 2005 | 221 | 0.270 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2012 | 345 | 0.270 |
Why?
|
| Spinal Neoplasms | 4 | 2014 | 716 | 0.260 |
Why?
|
| Leadership | 3 | 2018 | 1371 | 0.260 |
Why?
|
| Prejudice | 2 | 2007 | 571 | 0.260 |
Why?
|
| Carboplatin | 3 | 2021 | 788 | 0.250 |
Why?
|
| Survival Rate | 36 | 2015 | 12721 | 0.250 |
Why?
|
| Prednisolone | 5 | 1994 | 326 | 0.240 |
Why?
|
| Parental Leave | 2 | 2021 | 91 | 0.240 |
Why?
|
| Brain Stem | 4 | 2022 | 857 | 0.240 |
Why?
|
| Eye Neoplasms | 4 | 2003 | 306 | 0.240 |
Why?
|
| Preceptorship | 1 | 2004 | 56 | 0.240 |
Why?
|
| Radiation Oncology | 2 | 2022 | 563 | 0.240 |
Why?
|
| Pituitary Irradiation | 2 | 1994 | 14 | 0.230 |
Why?
|
| Academic Medical Centers | 3 | 2017 | 2751 | 0.230 |
Why?
|
| Organs at Risk | 6 | 2022 | 358 | 0.230 |
Why?
|
| Radiation Injuries, Experimental | 4 | 1994 | 88 | 0.230 |
Why?
|
| Cyclophosphamide | 18 | 2015 | 2218 | 0.220 |
Why?
|
| Cisplatin | 8 | 2015 | 1645 | 0.220 |
Why?
|
| Etanidazole | 1 | 2003 | 22 | 0.220 |
Why?
|
| Cysts | 1 | 2009 | 681 | 0.220 |
Why?
|
| Treatment Outcome | 53 | 2021 | 64379 | 0.220 |
Why?
|
| Radiotherapy, Adjuvant | 11 | 2021 | 1791 | 0.220 |
Why?
|
| Young Adult | 33 | 2024 | 58808 | 0.210 |
Why?
|
| Radiology Department, Hospital | 1 | 2006 | 405 | 0.210 |
Why?
|
| Relative Biological Effectiveness | 7 | 2021 | 312 | 0.210 |
Why?
|
| Stereotaxic Techniques | 5 | 1996 | 549 | 0.200 |
Why?
|
| Retrospective Studies | 49 | 2023 | 80170 | 0.200 |
Why?
|
| Adult | 96 | 2024 | 219916 | 0.190 |
Why?
|
| Alopecia | 4 | 2014 | 414 | 0.190 |
Why?
|
| Thoracic Neoplasms | 3 | 2014 | 266 | 0.190 |
Why?
|
| Survival Analysis | 16 | 2016 | 10112 | 0.190 |
Why?
|
| Fund Raising | 1 | 2021 | 49 | 0.190 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 3 | 2015 | 100 | 0.190 |
Why?
|
| Olfaction Disorders | 1 | 2024 | 224 | 0.190 |
Why?
|
| Dose-Response Relationship, Radiation | 12 | 2008 | 881 | 0.190 |
Why?
|
| Cancer Care Facilities | 1 | 2004 | 424 | 0.190 |
Why?
|
| Brain Stem Neoplasms | 1 | 2003 | 190 | 0.180 |
Why?
|
| Health Care Rationing | 1 | 2004 | 434 | 0.180 |
Why?
|
| Cognition | 9 | 2021 | 6955 | 0.180 |
Why?
|
| Memory Disorders | 5 | 2018 | 1198 | 0.180 |
Why?
|
| Intelligence | 5 | 2018 | 921 | 0.180 |
Why?
|
| Organizational Policy | 2 | 2021 | 429 | 0.170 |
Why?
|
| Growth Disorders | 3 | 2022 | 653 | 0.170 |
Why?
|
| Prognosis | 29 | 2016 | 29558 | 0.170 |
Why?
|
| Diabetes Insipidus | 2 | 2016 | 144 | 0.170 |
Why?
|
| Age Factors | 15 | 2021 | 18357 | 0.170 |
Why?
|
| Linear Energy Transfer | 3 | 2017 | 152 | 0.170 |
Why?
|
| Doxorubicin | 19 | 2015 | 2209 | 0.170 |
Why?
|
| Mentors | 1 | 2004 | 660 | 0.160 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 1793 | 0.160 |
Why?
|
| Optic Nerve Neoplasms | 1 | 1999 | 45 | 0.160 |
Why?
|
| Sex Factors | 12 | 2021 | 10505 | 0.160 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2021 | 257 | 0.160 |
Why?
|
| Lymphopenia | 1 | 2021 | 280 | 0.160 |
Why?
|
| Tectum Mesencephali | 1 | 1998 | 18 | 0.160 |
Why?
|
| Confidence Intervals | 3 | 2017 | 2925 | 0.150 |
Why?
|
| Spine | 2 | 2017 | 1111 | 0.150 |
Why?
|
| Medulla Oblongata | 1 | 1999 | 248 | 0.150 |
Why?
|
| Pituitary Gland | 2 | 2018 | 637 | 0.150 |
Why?
|
| SEER Program | 2 | 2013 | 1530 | 0.150 |
Why?
|
| Sarcoma | 6 | 2003 | 1785 | 0.150 |
Why?
|
| Meningeal Neoplasms | 4 | 2015 | 1247 | 0.150 |
Why?
|
| Wechsler Scales | 1 | 2018 | 257 | 0.150 |
Why?
|
| Drug Administration Schedule | 9 | 2013 | 4839 | 0.140 |
Why?
|
| Hypophysectomy | 2 | 1994 | 114 | 0.140 |
Why?
|
| Neuropsychological Tests | 9 | 2018 | 7023 | 0.140 |
Why?
|
| Pediatrics | 3 | 2018 | 3587 | 0.140 |
Why?
|
| Neoplasms, Multiple Primary | 5 | 2014 | 586 | 0.140 |
Why?
|
| Scattering, Radiation | 2 | 2017 | 488 | 0.140 |
Why?
|
| Spinal Cord | 3 | 2021 | 1815 | 0.140 |
Why?
|
| Mediastinal Neoplasms | 6 | 1997 | 402 | 0.140 |
Why?
|
| Abortion, Induced | 1 | 2022 | 460 | 0.140 |
Why?
|
| Soft Tissue Neoplasms | 3 | 1997 | 1152 | 0.130 |
Why?
|
| Gynecomastia | 1 | 2016 | 87 | 0.130 |
Why?
|
| Neurologic Examination | 3 | 1997 | 914 | 0.130 |
Why?
|
| Magnetic Resonance Spectroscopy | 5 | 2015 | 3758 | 0.130 |
Why?
|
| Neurofibromatosis 1 | 3 | 2007 | 560 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 11 | 2013 | 3527 | 0.130 |
Why?
|
| Time Factors | 19 | 2021 | 39873 | 0.130 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 1997 | 169 | 0.130 |
Why?
|
| Dactinomycin | 6 | 2006 | 304 | 0.130 |
Why?
|
| Survivors | 9 | 2020 | 2371 | 0.130 |
Why?
|
| Neoplasms | 6 | 2021 | 22030 | 0.120 |
Why?
|
| Rhabdoid Tumor | 2 | 2017 | 210 | 0.120 |
Why?
|
| Transplantation Conditioning | 4 | 2007 | 1588 | 0.120 |
Why?
|
| Endocrine System | 1 | 2015 | 112 | 0.120 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2015 | 58 | 0.120 |
Why?
|
| Teratoma | 3 | 2017 | 403 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 24 | 2016 | 36285 | 0.120 |
Why?
|
| Procarbazine | 9 | 2004 | 172 | 0.120 |
Why?
|
| Recurrence | 17 | 2023 | 8426 | 0.120 |
Why?
|
| Central Nervous System Diseases | 2 | 1997 | 520 | 0.120 |
Why?
|
| Mediastinum | 3 | 2004 | 266 | 0.120 |
Why?
|
| Prednisone | 13 | 2012 | 1565 | 0.120 |
Why?
|
| Leukemia, Lymphoid | 4 | 1988 | 310 | 0.110 |
Why?
|
| Ploidies | 2 | 1994 | 275 | 0.110 |
Why?
|
| Radiology | 2 | 2007 | 2102 | 0.110 |
Why?
|
| Leukemia, Experimental | 1 | 1994 | 225 | 0.110 |
Why?
|
| Pituitary Gland, Posterior | 1 | 2013 | 42 | 0.110 |
Why?
|
| Transplantation Chimera | 3 | 2007 | 595 | 0.110 |
Why?
|
| Neuroblastoma | 4 | 1997 | 1251 | 0.110 |
Why?
|
| Neoplasm Seeding | 1 | 1993 | 84 | 0.110 |
Why?
|
| Delayed Diagnosis | 2 | 2016 | 463 | 0.110 |
Why?
|
| Vomiting | 4 | 2024 | 651 | 0.110 |
Why?
|
| Hypothalamus | 1 | 2018 | 998 | 0.110 |
Why?
|
| Disease Progression | 11 | 2021 | 13468 | 0.110 |
Why?
|
| Nasal Cavity | 1 | 2015 | 304 | 0.110 |
Why?
|
| Nose Neoplasms | 1 | 2015 | 249 | 0.100 |
Why?
|
| Oligodendroglioma | 2 | 1993 | 279 | 0.100 |
Why?
|
| Monte Carlo Method | 5 | 2017 | 1256 | 0.100 |
Why?
|
| Nausea | 3 | 2024 | 677 | 0.100 |
Why?
|
| Pelvic Neoplasms | 1 | 2014 | 248 | 0.100 |
Why?
|
| Retinal Neoplasms | 1 | 2014 | 146 | 0.100 |
Why?
|
| Nervous System Diseases | 1 | 2003 | 1647 | 0.100 |
Why?
|
| Treatment Failure | 8 | 2015 | 2640 | 0.100 |
Why?
|
| Pineal Gland | 1 | 2013 | 157 | 0.100 |
Why?
|
| Neurosurgical Procedures | 1 | 2003 | 2055 | 0.100 |
Why?
|
| Skull | 2 | 1994 | 815 | 0.100 |
Why?
|
| Cohort Studies | 15 | 2022 | 41252 | 0.100 |
Why?
|
| Hippocampus | 3 | 2022 | 3736 | 0.100 |
Why?
|
| Brachytherapy | 3 | 1996 | 1236 | 0.100 |
Why?
|
| Brain | 15 | 2016 | 26951 | 0.090 |
Why?
|
| Dental Caries | 1 | 1995 | 420 | 0.090 |
Why?
|
| Incidence | 13 | 2017 | 21273 | 0.090 |
Why?
|
| Radiometry | 3 | 2018 | 813 | 0.090 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2015 | 1722 | 0.090 |
Why?
|
| Moyamoya Disease | 2 | 2021 | 256 | 0.090 |
Why?
|
| Prospective Studies | 18 | 2024 | 54136 | 0.090 |
Why?
|
| Quality of Life | 7 | 2020 | 13286 | 0.090 |
Why?
|
| Schools, Medical | 1 | 2017 | 877 | 0.090 |
Why?
|
| Mechlorethamine | 7 | 1993 | 129 | 0.090 |
Why?
|
| Postoperative Complications | 8 | 2003 | 15638 | 0.090 |
Why?
|
| Nervous System | 1 | 1994 | 543 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2016 | 6493 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 19 | 2009 | 20500 | 0.090 |
Why?
|
| Hypogonadism | 1 | 2016 | 800 | 0.090 |
Why?
|
| Endocrine System Diseases | 3 | 2018 | 249 | 0.090 |
Why?
|
| Periodicals as Topic | 3 | 2021 | 1462 | 0.090 |
Why?
|
| Hematologic Neoplasms | 4 | 2007 | 1890 | 0.090 |
Why?
|
| Oral Health | 1 | 1995 | 486 | 0.090 |
Why?
|
| Lung | 7 | 1995 | 9985 | 0.080 |
Why?
|
| Remission Induction | 9 | 2005 | 2388 | 0.080 |
Why?
|
| Behavior, Animal | 3 | 1994 | 1867 | 0.080 |
Why?
|
| Nervous System Neoplasms | 1 | 1990 | 91 | 0.080 |
Why?
|
| Cost Savings | 1 | 2015 | 918 | 0.080 |
Why?
|
| Vinblastine | 5 | 2012 | 487 | 0.080 |
Why?
|
| Ifosfamide | 3 | 2006 | 232 | 0.080 |
Why?
|
| Cranial Nerve Injuries | 1 | 2009 | 28 | 0.080 |
Why?
|
| Emollients | 1 | 2009 | 41 | 0.080 |
Why?
|
| Thorax | 2 | 2004 | 553 | 0.080 |
Why?
|
| Executive Function | 1 | 2017 | 1375 | 0.080 |
Why?
|
| Antineoplastic Agents | 6 | 2013 | 13591 | 0.080 |
Why?
|
| DNA, Neoplasm | 2 | 1997 | 1745 | 0.080 |
Why?
|
| Analysis of Variance | 7 | 2018 | 6233 | 0.080 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 1116 | 0.080 |
Why?
|
| Cognition Disorders | 5 | 2009 | 3975 | 0.080 |
Why?
|
| Risk Assessment | 6 | 2017 | 23883 | 0.080 |
Why?
|
| Pelvic Bones | 2 | 2010 | 270 | 0.080 |
Why?
|
| United States | 13 | 2022 | 72140 | 0.080 |
Why?
|
| Radiation Dosage | 5 | 2007 | 1956 | 0.070 |
Why?
|
| Lymphoma, Non-Hodgkin | 5 | 2003 | 1373 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 3617 | 0.070 |
Why?
|
| Hospitals | 1 | 2021 | 3888 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 2 | 2014 | 2882 | 0.070 |
Why?
|
| Cytogenetics | 1 | 2007 | 198 | 0.070 |
Why?
|
| Adenoma | 2 | 1996 | 2148 | 0.070 |
Why?
|
| Middle Aged | 44 | 2022 | 219560 | 0.070 |
Why?
|
| Hypopituitarism | 1 | 2009 | 250 | 0.070 |
Why?
|
| Injections, Spinal | 6 | 2005 | 317 | 0.070 |
Why?
|
| Pleural Effusion | 2 | 1989 | 342 | 0.070 |
Why?
|
| Chondrosarcoma | 1 | 2009 | 296 | 0.070 |
Why?
|
| Radiation-Protective Agents | 1 | 1986 | 88 | 0.070 |
Why?
|
| Brain Damage, Chronic | 3 | 1997 | 267 | 0.070 |
Why?
|
| Women | 1 | 2008 | 225 | 0.070 |
Why?
|
| Risk Factors | 22 | 2019 | 73806 | 0.070 |
Why?
|
| Proportional Hazards Models | 5 | 2015 | 12440 | 0.070 |
Why?
|
| Lymphocyte Transfusion | 2 | 2005 | 232 | 0.060 |
Why?
|
| Health Services Accessibility | 2 | 2019 | 5403 | 0.060 |
Why?
|
| Tumor Burden | 3 | 2021 | 1893 | 0.060 |
Why?
|
| Feasibility Studies | 5 | 2017 | 5199 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 1999 | 3526 | 0.060 |
Why?
|
| Acetylcysteine | 1 | 1986 | 261 | 0.060 |
Why?
|
| Aspartic Acid | 2 | 2004 | 576 | 0.060 |
Why?
|
| alpha-Fetoproteins | 2 | 2013 | 222 | 0.060 |
Why?
|
| Graft vs Host Disease | 8 | 2005 | 3024 | 0.060 |
Why?
|
| Hemorrhage | 1 | 1996 | 3400 | 0.060 |
Why?
|
| Cerebral Arteries | 1 | 2007 | 492 | 0.060 |
Why?
|
| Necrosis | 1 | 2009 | 1604 | 0.060 |
Why?
|
| Radiation Tolerance | 1 | 1986 | 480 | 0.060 |
Why?
|
| Body Height | 3 | 2013 | 1567 | 0.060 |
Why?
|
| Cerebral Hemorrhage | 1 | 1995 | 2650 | 0.060 |
Why?
|
| Physicians | 1 | 2021 | 4581 | 0.060 |
Why?
|
| Bacterial Vaccines | 2 | 1996 | 401 | 0.050 |
Why?
|
| Sacrum | 1 | 2005 | 277 | 0.050 |
Why?
|
| Chorionic Gonadotropin | 2 | 2013 | 457 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2003 | 6803 | 0.050 |
Why?
|
| Authorship | 1 | 2006 | 281 | 0.050 |
Why?
|
| Graft vs Tumor Effect | 1 | 2003 | 68 | 0.050 |
Why?
|
| Specialization | 1 | 2008 | 776 | 0.050 |
Why?
|
| Cranial Fossa, Posterior | 2 | 1995 | 135 | 0.050 |
Why?
|
| Hearing Loss | 1 | 1990 | 780 | 0.050 |
Why?
|
| Staff Development | 1 | 2004 | 229 | 0.050 |
Why?
|
| Bibliometrics | 1 | 2006 | 349 | 0.050 |
Why?
|
| Hair Follicle | 1 | 2004 | 210 | 0.050 |
Why?
|
| Cytarabine | 7 | 2005 | 696 | 0.050 |
Why?
|
| Ribs | 2 | 2003 | 252 | 0.050 |
Why?
|
| Growth Plate | 2 | 2017 | 274 | 0.050 |
Why?
|
| Growth | 2 | 1997 | 365 | 0.050 |
Why?
|
| Histocompatibility | 1 | 2003 | 316 | 0.050 |
Why?
|
| Hydrocephalus | 2 | 1999 | 764 | 0.050 |
Why?
|
| Vision Disorders | 2 | 2021 | 1084 | 0.050 |
Why?
|
| Glioblastoma | 4 | 2003 | 3480 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2007 | 629 | 0.050 |
Why?
|
| Women, Working | 1 | 2002 | 86 | 0.050 |
Why?
|
| Actuarial Analysis | 4 | 1995 | 374 | 0.050 |
Why?
|
| Boston | 3 | 2017 | 9304 | 0.050 |
Why?
|
| Publishing | 1 | 2008 | 833 | 0.050 |
Why?
|
| Kidney Diseases | 2 | 1988 | 2083 | 0.040 |
Why?
|
| Akinetic Mutism | 1 | 2000 | 11 | 0.040 |
Why?
|
| Testis | 2 | 2016 | 794 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 2009 | 1160 | 0.040 |
Why?
|
| Testicular Neoplasms | 3 | 2021 | 801 | 0.040 |
Why?
|
| Models, Economic | 2 | 2015 | 715 | 0.040 |
Why?
|
| Memory, Short-Term | 2 | 2017 | 979 | 0.040 |
Why?
|
| Lymphocyte Depletion | 4 | 2003 | 602 | 0.040 |
Why?
|
| Career Choice | 2 | 2006 | 752 | 0.040 |
Why?
|
| Forecasting | 1 | 2009 | 2920 | 0.040 |
Why?
|
| Medicine | 1 | 2008 | 942 | 0.040 |
Why?
|
| Body Weight | 3 | 2003 | 4603 | 0.040 |
Why?
|
| Developed Countries | 1 | 2022 | 440 | 0.040 |
Why?
|
| Radiography | 5 | 2015 | 6955 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 778 | 0.040 |
Why?
|
| Risk | 6 | 2013 | 9599 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2010 | 2276 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2007 | 1599 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2004 | 989 | 0.040 |
Why?
|
| Program Development | 1 | 2004 | 1297 | 0.040 |
Why?
|
| Ataxia Telangiectasia | 1 | 1999 | 107 | 0.040 |
Why?
|
| Transplantation, Autologous | 7 | 2007 | 2114 | 0.040 |
Why?
|
| Hypothalamic Neoplasms | 1 | 1997 | 21 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 1705 | 0.040 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 1999 | 198 | 0.040 |
Why?
|
| Diencephalon | 1 | 1997 | 54 | 0.040 |
Why?
|
| Diagnosis, Differential | 6 | 2016 | 12951 | 0.040 |
Why?
|
| Job Satisfaction | 1 | 2002 | 539 | 0.040 |
Why?
|
| Eosinophilic Granuloma | 1 | 1997 | 27 | 0.040 |
Why?
|
| Vaccines, Conjugate | 2 | 1996 | 328 | 0.040 |
Why?
|
| Infant, Newborn | 7 | 2013 | 26182 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 1990 | 2457 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2007 | 2825 | 0.040 |
Why?
|
| Salvage Therapy | 4 | 2002 | 1268 | 0.040 |
Why?
|
| Brain Diseases | 2 | 1997 | 1541 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2004 | 1431 | 0.040 |
Why?
|
| Personnel Turnover | 1 | 2017 | 86 | 0.040 |
Why?
|
| Thyroid Gland | 2 | 2017 | 1168 | 0.040 |
Why?
|
| Proto-Oncogenes | 1 | 1997 | 320 | 0.030 |
Why?
|
| Cardiovascular System | 1 | 2004 | 835 | 0.030 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 1998 | 195 | 0.030 |
Why?
|
| Failure to Thrive | 1 | 1997 | 140 | 0.030 |
Why?
|
| Chromosome Aberrations | 2 | 1995 | 1764 | 0.030 |
Why?
|
| Retreatment | 1 | 1998 | 596 | 0.030 |
Why?
|
| Neuroma, Acoustic | 3 | 1996 | 459 | 0.030 |
Why?
|
| Asparaginase | 3 | 2000 | 240 | 0.030 |
Why?
|
| Breast Neoplasms | 4 | 2008 | 21017 | 0.030 |
Why?
|
| Polysaccharides, Bacterial | 2 | 1996 | 574 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2004 | 2490 | 0.030 |
Why?
|
| Bone Marrow | 4 | 1991 | 2909 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 1997 | 638 | 0.030 |
Why?
|
| Prolactinoma | 1 | 1996 | 113 | 0.030 |
Why?
|
| Haemophilus Vaccines | 1 | 1995 | 71 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 627 | 0.030 |
Why?
|
| Leukemic Infiltration | 1 | 1995 | 47 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2006 | 2167 | 0.030 |
Why?
|
| Bleomycin | 2 | 1993 | 495 | 0.030 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2004 | 1066 | 0.030 |
Why?
|
| Laparotomy | 2 | 1995 | 465 | 0.030 |
Why?
|
| Central Nervous System | 3 | 2013 | 1333 | 0.030 |
Why?
|
| Anesthesia, Local | 2 | 1995 | 276 | 0.030 |
Why?
|
| Headache | 2 | 2021 | 1248 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2015 | 251 | 0.030 |
Why?
|
| Cephalometry | 2 | 1994 | 382 | 0.030 |
Why?
|
| Cerebellum | 3 | 2015 | 1497 | 0.030 |
Why?
|
| Topotecan | 1 | 2015 | 132 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 1998 | 987 | 0.030 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2005 | 1402 | 0.030 |
Why?
|
| Radiation Protection | 1 | 1998 | 425 | 0.030 |
Why?
|
| Gingivitis | 1 | 1995 | 124 | 0.030 |
Why?
|
| Skull Base | 1 | 1997 | 291 | 0.030 |
Why?
|
| Iodine Radioisotopes | 2 | 1995 | 1032 | 0.030 |
Why?
|
| Dental Plaque | 1 | 1995 | 209 | 0.030 |
Why?
|
| Ganglioglioma | 1 | 1994 | 36 | 0.030 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 1994 | 219 | 0.030 |
Why?
|
| Burkitt Lymphoma | 1 | 1996 | 333 | 0.030 |
Why?
|
| Fatigue | 1 | 2021 | 1542 | 0.030 |
Why?
|
| Transplantation, Homologous | 5 | 2007 | 4809 | 0.030 |
Why?
|
| Dacarbazine | 2 | 1993 | 559 | 0.030 |
Why?
|
| Rats | 4 | 1994 | 23681 | 0.030 |
Why?
|
| Craniotomy | 2 | 1995 | 741 | 0.030 |
Why?
|
| Reoperation | 2 | 2001 | 4282 | 0.030 |
Why?
|
| Pentetic Acid | 1 | 1993 | 209 | 0.030 |
Why?
|
| Neutropenia | 2 | 2012 | 884 | 0.030 |
Why?
|
| Awards and Prizes | 1 | 2017 | 359 | 0.030 |
Why?
|
| Equipment Design | 2 | 1998 | 3507 | 0.030 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 1995 | 407 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 1994 | 8144 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2000 | 1927 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2004 | 8554 | 0.030 |
Why?
|
| Rats, Inbred Strains | 2 | 1990 | 2090 | 0.030 |
Why?
|
| Medical Records | 1 | 1998 | 1406 | 0.030 |
Why?
|
| Parents | 2 | 2018 | 3548 | 0.030 |
Why?
|
| Aged | 17 | 2004 | 168217 | 0.030 |
Why?
|
| Choline | 2 | 2004 | 513 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 1995 | 859 | 0.030 |
Why?
|
| Seizures | 2 | 2016 | 2919 | 0.030 |
Why?
|
| Particle Accelerators | 2 | 1994 | 174 | 0.020 |
Why?
|
| Lymphocytes | 2 | 1997 | 2610 | 0.020 |
Why?
|
| Patient Selection | 1 | 2004 | 4244 | 0.020 |
Why?
|
| T-Lymphocytes | 6 | 2003 | 10171 | 0.020 |
Why?
|
| Bone Marrow Purging | 1 | 1991 | 108 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2000 | 1530 | 0.020 |
Why?
|
| Optic Nerve Diseases | 1 | 1995 | 342 | 0.020 |
Why?
|
| Thallium Radioisotopes | 1 | 1991 | 138 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 1295 | 0.020 |
Why?
|
| Neuroglia | 1 | 1997 | 944 | 0.020 |
Why?
|
| Organotechnetium Compounds | 1 | 1991 | 129 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 1999 | 1613 | 0.020 |
Why?
|
| Calcinosis | 2 | 1997 | 1467 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2015 | 5484 | 0.020 |
Why?
|
| Curriculum | 1 | 2004 | 3717 | 0.020 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2011 | 42 | 0.020 |
Why?
|
| Pneumococcal Infections | 1 | 1996 | 503 | 0.020 |
Why?
|
| Mesonephroma | 1 | 1990 | 21 | 0.020 |
Why?
|
| Esophagus | 1 | 2017 | 1023 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2007 | 5759 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 1999 | 1840 | 0.020 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1991 | 106 | 0.020 |
Why?
|
| Maxillofacial Development | 1 | 1990 | 87 | 0.020 |
Why?
|
| Intestine, Small | 1 | 2017 | 1207 | 0.020 |
Why?
|
| Tooth Diseases | 1 | 1990 | 74 | 0.020 |
Why?
|
| Genital Neoplasms, Male | 1 | 1990 | 68 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2004 | 4048 | 0.020 |
Why?
|
| Anesthesia, General | 2 | 1995 | 1165 | 0.020 |
Why?
|
| Streptococcus pneumoniae | 1 | 1996 | 732 | 0.020 |
Why?
|
| Ricin | 1 | 1990 | 70 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 1993 | 823 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2021 | 2312 | 0.020 |
Why?
|
| Oximes | 1 | 1991 | 303 | 0.020 |
Why?
|
| Comprehension | 1 | 2015 | 619 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 1998 | 2509 | 0.020 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 1991 | 221 | 0.020 |
Why?
|
| Organometallic Compounds | 1 | 1993 | 648 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 1995 | 1007 | 0.020 |
Why?
|
| Audiometry | 1 | 1990 | 253 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 1997 | 1594 | 0.020 |
Why?
|
| Immunotoxins | 1 | 1990 | 175 | 0.020 |
Why?
|
| Aneuploidy | 1 | 1993 | 551 | 0.020 |
Why?
|
| Histocompatibility Testing | 2 | 2007 | 717 | 0.020 |
Why?
|
| Lymphoid Tissue | 1 | 1991 | 445 | 0.020 |
Why?
|
| Hypertension, Renal | 1 | 1989 | 135 | 0.020 |
Why?
|
| Drug Interactions | 1 | 1994 | 1414 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 2015 | 977 | 0.020 |
Why?
|
| Trachea | 2 | 1995 | 1081 | 0.020 |
Why?
|
| Sex Distribution | 2 | 2006 | 2283 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1990 | 430 | 0.020 |
Why?
|
| Brain Chemistry | 2 | 2004 | 959 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 2 | 1988 | 1628 | 0.020 |
Why?
|
| Antigens, Differentiation | 2 | 1990 | 911 | 0.020 |
Why?
|
| Leukemia | 3 | 1991 | 1519 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2013 | 1812 | 0.020 |
Why?
|
| Femur Head | 1 | 2010 | 297 | 0.020 |
Why?
|
| Lomustine | 1 | 1988 | 60 | 0.020 |
Why?
|
| Pericarditis | 1 | 1990 | 133 | 0.020 |
Why?
|
| Carmustine | 1 | 1988 | 138 | 0.020 |
Why?
|
| Neprilysin | 2 | 1988 | 471 | 0.020 |
Why?
|
| Prostatic Neoplasms | 2 | 2010 | 11336 | 0.020 |
Why?
|
| Gadolinium | 1 | 1993 | 959 | 0.020 |
Why?
|
| Memory | 1 | 2018 | 2179 | 0.020 |
Why?
|
| Cause of Death | 2 | 2013 | 3674 | 0.020 |
Why?
|
| Family Leave | 1 | 2007 | 18 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2002 | 3867 | 0.020 |
Why?
|
| Urogenital Neoplasms | 1 | 1989 | 135 | 0.020 |
Why?
|
| Statistics as Topic | 2 | 2008 | 2359 | 0.020 |
Why?
|
| Intelligence Tests | 3 | 1995 | 500 | 0.020 |
Why?
|
| Retina | 1 | 1998 | 2637 | 0.020 |
Why?
|
| World Health Organization | 1 | 2013 | 1312 | 0.020 |
Why?
|
| Anemia, Hemolytic | 1 | 1988 | 163 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2007 | 5865 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 1987 | 351 | 0.020 |
Why?
|
| Circle of Willis | 1 | 2007 | 79 | 0.020 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2013 | 781 | 0.020 |
Why?
|
| Diaphragm | 1 | 1988 | 351 | 0.020 |
Why?
|
| Splenectomy | 1 | 2008 | 391 | 0.020 |
Why?
|
| Bone Marrow Cells | 2 | 1991 | 2414 | 0.020 |
Why?
|
| Lymphoma | 2 | 1986 | 1896 | 0.020 |
Why?
|
| Animals | 10 | 1999 | 167777 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 2014 | 1688 | 0.020 |
Why?
|
| Massachusetts | 2 | 2011 | 8823 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2018 | 3891 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2005 | 5649 | 0.020 |
Why?
|
| Hormones | 1 | 1990 | 869 | 0.020 |
Why?
|
| Dysgerminoma | 1 | 1986 | 66 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2007 | 10747 | 0.020 |
Why?
|
| Vision, Ocular | 1 | 1990 | 454 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 1994 | 1825 | 0.020 |
Why?
|
| Wilms Tumor | 1 | 1989 | 375 | 0.020 |
Why?
|
| Family | 2 | 2007 | 3188 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1991 | 1066 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2007 | 677 | 0.020 |
Why?
|
| Graves Disease | 1 | 1988 | 238 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2007 | 225 | 0.020 |
Why?
|
| Biopsy | 3 | 2004 | 6768 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 12096 | 0.020 |
Why?
|
| Specialty Boards | 1 | 2007 | 235 | 0.020 |
Why?
|
| Neuralgia | 1 | 2012 | 600 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 1990 | 1387 | 0.020 |
Why?
|
| X-Rays | 1 | 1986 | 307 | 0.020 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 7817 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 15785 | 0.020 |
Why?
|
| Pregnancy | 2 | 2022 | 29742 | 0.020 |
Why?
|
| Graft Rejection | 2 | 2005 | 4426 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2005 | 2504 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2014 | 2642 | 0.020 |
Why?
|
| Family Practice | 1 | 2007 | 509 | 0.020 |
Why?
|
| Bacterial Capsules | 2 | 1996 | 242 | 0.010 |
Why?
|
| Image Enhancement | 1 | 1995 | 2880 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1996 | 3142 | 0.010 |
Why?
|
| Drug Hypersensitivity | 1 | 1993 | 915 | 0.010 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2004 | 61 | 0.010 |
Why?
|
| Urinary Bladder | 1 | 2010 | 1166 | 0.010 |
Why?
|
| Students, Medical | 1 | 2017 | 1927 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1994 | 6293 | 0.010 |
Why?
|
| Organizational Culture | 1 | 2007 | 506 | 0.010 |
Why?
|
| Antigens, CD | 2 | 1991 | 3997 | 0.010 |
Why?
|
| Leukocyte Transfusion | 1 | 2003 | 56 | 0.010 |
Why?
|
| Protozoan Infections | 1 | 2003 | 39 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 1986 | 1153 | 0.010 |
Why?
|
| Public Policy | 1 | 2007 | 559 | 0.010 |
Why?
|
| Kidney | 2 | 2017 | 7016 | 0.010 |
Why?
|
| Antigens, Neoplasm | 2 | 1988 | 1997 | 0.010 |
Why?
|
| Pneumonia | 3 | 1990 | 2129 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2014 | 10146 | 0.010 |
Why?
|
| Comorbidity | 2 | 2008 | 10495 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1998 | 3599 | 0.010 |
Why?
|
| Heart Block | 1 | 2004 | 392 | 0.010 |
Why?
|
| Apoptosis | 1 | 1999 | 9468 | 0.010 |
Why?
|
| Registries | 1 | 2019 | 8176 | 0.010 |
Why?
|
| HLA Antigens | 2 | 2003 | 1368 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 2008 | 796 | 0.010 |
Why?
|
| Creatine | 1 | 2004 | 426 | 0.010 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2003 | 178 | 0.010 |
Why?
|
| Myelodysplastic Syndromes | 2 | 1990 | 1392 | 0.010 |
Why?
|
| Tachycardia | 1 | 2004 | 600 | 0.010 |
Why?
|
| Liver Neoplasms | 2 | 1995 | 4313 | 0.010 |
Why?
|
| Patient Care Team | 1 | 1993 | 2504 | 0.010 |
Why?
|
| Aspergillosis | 1 | 2003 | 243 | 0.010 |
Why?
|
| Random Allocation | 2 | 1996 | 2385 | 0.010 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2003 | 237 | 0.010 |
Why?
|
| Liver | 1 | 2017 | 7502 | 0.010 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2008 | 1096 | 0.010 |
Why?
|
| Mice | 6 | 1999 | 81107 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2005 | 1975 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 2 | 2003 | 2821 | 0.010 |
Why?
|
| Algorithms | 4 | 2007 | 13959 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1990 | 1910 | 0.010 |
Why?
|
| Learning | 1 | 1990 | 1739 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 1990 | 2621 | 0.010 |
Why?
|
| Contrast Media | 1 | 1993 | 5298 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 2210 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2013 | 6201 | 0.010 |
Why?
|
| Emergencies | 1 | 1986 | 1209 | 0.010 |
Why?
|
| Lactic Acid | 1 | 2004 | 1133 | 0.010 |
Why?
|
| Lymphoma, Follicular | 1 | 2003 | 453 | 0.010 |
Why?
|
| Spinal Cord Injuries | 1 | 2007 | 925 | 0.010 |
Why?
|
| Longitudinal Studies | 2 | 2013 | 14481 | 0.010 |
Why?
|
| Neurotrophin 3 | 1 | 1999 | 61 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2004 | 1338 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1999 | 306 | 0.010 |
Why?
|
| Receptor, trkC | 1 | 1999 | 63 | 0.010 |
Why?
|
| Heart Conduction System | 1 | 2004 | 1011 | 0.010 |
Why?
|
| Karyotyping | 2 | 1990 | 1171 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 1996 | 3801 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1995 | 8946 | 0.010 |
Why?
|
| Blast Crisis | 1 | 1998 | 101 | 0.010 |
Why?
|
| Thymus Gland | 1 | 2003 | 1244 | 0.010 |
Why?
|
| Leucovorin | 1 | 2000 | 641 | 0.010 |
Why?
|
| Eye Diseases | 1 | 2003 | 651 | 0.010 |
Why?
|
| Transcription Factors | 1 | 1997 | 12096 | 0.010 |
Why?
|
| Graft Survival | 3 | 1996 | 3794 | 0.010 |
Why?
|
| Ganglioneuroblastoma | 1 | 1997 | 10 | 0.010 |
Why?
|
| Methods | 2 | 1988 | 1074 | 0.010 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 489 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 2 | 1991 | 9160 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 1995 | 5349 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2007 | 6353 | 0.010 |
Why?
|
| Logistic Models | 2 | 2003 | 13276 | 0.010 |
Why?
|
| Cell Survival | 1 | 1987 | 5781 | 0.010 |
Why?
|
| Models, Biological | 1 | 1993 | 9461 | 0.010 |
Why?
|
| Virus Diseases | 1 | 2003 | 719 | 0.010 |
Why?
|
| Radiation Pneumonitis | 1 | 1997 | 102 | 0.010 |
Why?
|
| Heart | 1 | 1990 | 4382 | 0.010 |
Why?
|
| Heart Valve Diseases | 1 | 2004 | 1033 | 0.010 |
Why?
|
| Exercise Test | 1 | 2004 | 2121 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2003 | 1788 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2004 | 1894 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1999 | 585 | 0.010 |
Why?
|
| Acute Disease | 3 | 1993 | 7225 | 0.010 |
Why?
|
| Maximal Expiratory Flow Rate | 1 | 1995 | 42 | 0.010 |
Why?
|
| Platelet Count | 1 | 1998 | 775 | 0.010 |
Why?
|
| Nerve Growth Factors | 1 | 1999 | 562 | 0.010 |
Why?
|
| Ethmoid Sinusitis | 1 | 1995 | 25 | 0.010 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 1997 | 350 | 0.010 |
Why?
|
| Hematopoiesis | 1 | 2005 | 2047 | 0.010 |
Why?
|
| Serotyping | 1 | 1996 | 324 | 0.010 |
Why?
|
| Meningococcal Vaccines | 1 | 1995 | 94 | 0.010 |
Why?
|
| Brain Injuries | 1 | 2007 | 2044 | 0.010 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 1997 | 300 | 0.010 |
Why?
|
| Maxillary Sinusitis | 1 | 1995 | 41 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2007 | 3671 | 0.010 |
Why?
|
| Thyroid Neoplasms | 1 | 2008 | 2332 | 0.010 |
Why?
|
| Critical Care | 1 | 2007 | 2692 | 0.010 |
Why?
|
| Exudates and Transudates | 1 | 1995 | 174 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1994 | 18125 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1986 | 3485 | 0.010 |
Why?
|
| Genetic Diseases, Inborn | 1 | 1999 | 601 | 0.010 |
Why?
|
| Pons | 1 | 1995 | 239 | 0.010 |
Why?
|
| Pulmonary Atelectasis | 1 | 1995 | 143 | 0.010 |
Why?
|
| Immunoglobulin G | 2 | 1996 | 4540 | 0.010 |
Why?
|
| Lymphography | 1 | 1994 | 188 | 0.010 |
Why?
|
| Immobilization | 1 | 1994 | 227 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2004 | 4901 | 0.010 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 1997 | 677 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 25953 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1995 | 1378 | 0.010 |
Why?
|
| Linear Models | 1 | 2003 | 5861 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 1990 | 4402 | 0.010 |
Why?
|
| Educational Measurement | 1 | 2000 | 1248 | 0.010 |
Why?
|
| Mannitol | 1 | 1993 | 180 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1999 | 3593 | 0.010 |
Why?
|
| Heart Rate | 1 | 2004 | 4166 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2000 | 1398 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 1989 | 4312 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1999 | 3602 | 0.010 |
Why?
|
| Pneumococcal Vaccines | 1 | 1996 | 397 | 0.010 |
Why?
|
| Technetium Tc 99m Exametazime | 1 | 1991 | 61 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 4567 | 0.010 |
Why?
|
| Echocardiography | 1 | 2004 | 4962 | 0.010 |
Why?
|
| Immunization | 1 | 1996 | 1227 | 0.010 |
Why?
|
| Dental Enamel Hypoplasia | 1 | 1990 | 23 | 0.010 |
Why?
|
| Radiology, Interventional | 1 | 1995 | 475 | 0.010 |
Why?
|
| Mammography | 1 | 2002 | 2427 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1999 | 6127 | 0.010 |
Why?
|
| Syndrome | 1 | 1997 | 3262 | 0.010 |
Why?
|
| Cough | 1 | 1995 | 594 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2004 | 6363 | 0.010 |
Why?
|
| Calibration | 1 | 1993 | 814 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 1 | 1991 | 248 | 0.010 |
Why?
|
| Odontogenesis | 1 | 1990 | 65 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 1998 | 1172 | 0.010 |
Why?
|
| Drug Therapy | 1 | 1994 | 503 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 1995 | 1680 | 0.010 |
Why?
|
| Conscious Sedation | 1 | 1995 | 529 | 0.010 |
Why?
|
| Tooth Root | 1 | 1990 | 162 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1991 | 523 | 0.010 |
Why?
|
| Airway Obstruction | 1 | 1995 | 661 | 0.010 |
Why?
|
| Genes, myc | 1 | 1991 | 391 | 0.010 |
Why?
|
| Chimera | 1 | 1991 | 452 | 0.010 |
Why?
|
| Hematocrit | 1 | 1991 | 627 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 14641 | 0.010 |
Why?
|
| Hearing Disorders | 1 | 1989 | 126 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 1999 | 2858 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 1991 | 677 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 1993 | 13245 | 0.000 |
Why?
|
| Blood Urea Nitrogen | 1 | 1988 | 186 | 0.000 |
Why?
|
| Orchiectomy | 1 | 1990 | 470 | 0.000 |
Why?
|
| Drug Evaluation | 1 | 1990 | 638 | 0.000 |
Why?
|
| Predictive Value of Tests | 1 | 2004 | 15225 | 0.000 |
Why?
|
| Mice, Inbred Strains | 1 | 1991 | 1759 | 0.000 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1995 | 1489 | 0.000 |
Why?
|
| Aged, 80 and over | 2 | 2003 | 58681 | 0.000 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1991 | 533 | 0.000 |
Why?
|
| Chromosome Mapping | 1 | 1995 | 4624 | 0.000 |
Why?
|
| Incisor | 1 | 1988 | 174 | 0.000 |
Why?
|
| Intubation, Intratracheal | 1 | 1995 | 1327 | 0.000 |
Why?
|
| Meningioma | 1 | 1996 | 1217 | 0.000 |
Why?
|
| Mice, Inbred C3H | 1 | 1988 | 915 | 0.000 |
Why?
|
| Pulmonary Fibrosis | 1 | 1990 | 506 | 0.000 |
Why?
|
| Mediastinal Emphysema | 1 | 1986 | 29 | 0.000 |
Why?
|
| Cell Line | 2 | 1990 | 15594 | 0.000 |
Why?
|
| Gene Amplification | 1 | 1991 | 1085 | 0.000 |
Why?
|
| Body Mass Index | 1 | 2003 | 12876 | 0.000 |
Why?
|
| Neoplasm Proteins | 1 | 1997 | 3609 | 0.000 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1991 | 733 | 0.000 |
Why?
|
| Stomatitis | 1 | 1988 | 271 | 0.000 |
Why?
|
| Gene Rearrangement | 1 | 1990 | 1122 | 0.000 |
Why?
|
| Osteosarcoma | 1 | 1990 | 897 | 0.000 |
Why?
|
| Lymph Node Excision | 1 | 1990 | 1303 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 1999 | 12760 | 0.000 |
Why?
|
| Respiration, Artificial | 1 | 1995 | 2618 | 0.000 |
Why?
|
| Genital Neoplasms, Female | 1 | 1989 | 533 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1986 | 1593 | 0.000 |
Why?
|
| DNA-Binding Proteins | 1 | 1997 | 9575 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 1997 | 22031 | 0.000 |
Why?
|
| Lymphatic Metastasis | 1 | 1987 | 2943 | 0.000 |
Why?
|
| Electroencephalography | 1 | 1994 | 6187 | 0.000 |
Why?
|
| Stem Cells | 1 | 1991 | 3521 | 0.000 |
Why?
|
| Signal Transduction | 1 | 1999 | 23341 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1990 | 9266 | 0.000 |
Why?
|
| B-Lymphocytes | 1 | 1987 | 4738 | 0.000 |
Why?
|
| Cardiovascular Diseases | 1 | 1995 | 15396 | 0.000 |
Why?
|
| Mutation | 1 | 1993 | 29915 | 0.000 |
Why?
|